Cover Image
市场调查报告书

全球癌症的精密医疗IT解决方案 - 关注企业:2017年

Global Precision Medicine IT Solutions for Oncology - Companies to Action, 2017

出版商 Frost & Sullivan 商品编码 596045
出版日期 内容信息 英文 81 Pages
商品交期: 最快1-2个工作天内
价格
Back to Top
全球癌症的精密医疗IT解决方案 - 关注企业:2017年 Global Precision Medicine IT Solutions for Oncology - Companies to Action, 2017
出版日期: 2017年11月24日 内容信息: 英文 81 Pages
简介

本报告提供癌症的精密医疗领域中提供有希望、破坏性、前导性的解决方案的供应商的简介。

第1章 摘要整理

第2章 关注企业概要

  • 产业融合促进的破坏与创新
  • 医疗的汇流产生机会及威胁双方
  • 关注企业 - 破坏目前医疗产业范例的可能性

第3章 数位健康产业的概述

  • 广泛产业融合的数位健康的优点
  • 数位健康的优先级
  • 数位健康市场区分、汇流

第4章 癌症精密医疗市场概要

  • 精密医疗是什么?
  • 市场课题、机会、顾虑事项
  • 精密医疗引进的现状
  • 精密医疗的主要数据来源
  • 癌症的精密医疗的影响
  • 主要市场影响者的影响
  • 癌症精密医疗的操作架构
  • 癌症精密医疗的操作架构的说明
  • 相关利益者的数位健康解决方案
  • 持续性照护整体适用的数位健康解决方案
  • 支持数位健康企业:业者情势癌症精密医疗
  • 主要产业需求、业者情势
  • 癌症精密医疗的IT解决方案:C2A的主要调查结果

第5章 C2A简介

  • 2bPrecise (Allscripts)
  • Cerner
  • GenomOncology
  • IBM Watson Health
  • N-of-One
  • NantHealth
  • Navican (an Intermountain Healthcare Company)
  • Quest Diagnostics
  • Royal Philips
  • Via Oncology

第6章 结论

第7章 附录

第8章 关于Frost&Sullivan

目录
Product Code: K1E9-48

Early Movers Expect to Facilitate Evidence-Based Cancer Care

Definition:

Precision medicine for oncology is defined as patient-specific cancer care that is aided by a targeted software suite. The realm of precision medicine is determined by providers' willingness and ability to capture and normalize disparate patient data - including clinical, socioeconomic, behavioral, and genomic - to identify evidence-based treatments that are ideal for each patient.

Report Outlook:

This report profiles vendors that are offering promising, disruptive, and pioneering solutions across diverse domains in precision medicine for oncology. It brings the most recent and successful and/or high-potential companies to light. The focus has been to identify vendors that bring in the advantage purely in terms of analytics - not other components of data management and meaningful use. These companies create extraordinary value for their internal and external stakeholders by showcasing visionary leadership and implementing industry best practices, and through business model innovation.

Market Snapshot:

Healthcare IT ecosystems around the world are not adequately equipped to facilitate seamless data interoperability across the care continuum, which is fundamental for enabling precision medicine. For example, even in the United States - arguably a progressive and technologically sophisticated digital health market - the regulatory framework (e.g., CMS, ONC, HHS*) fails to introduce clear mandates that safeguard the privacy of patients willing to share medical data for the Precision Medicine Initiative; outline incentive guidelines for patients accepting precision medicine approaches; introduce reimbursement programs for providers investing in precision medicine systems; and encourage consideration of patients' sociobehavioral state to adjust treatment pathways. As a result, most providers have yet to realize tangible ROIs from precision medicine pilots.

Poor support from ecosystem-level partners (incumbent EHR, RCM, HIE, and clinical decision support system vendors) coupled with a lack of ROI evidence validates that the precision medicine market is still in its infancy.

Despite the low levels of supply-side maturity, more providers will embrace precision medicine, especially in the United States, to improve patient outcomes and rationalize corporate profitability due to mandatory or voluntary involvement in value-based care and the Precision Medicine Initiative. They will depend on external specialist firms to develop proprietary tools or introduce third-party platforms.

Precision medicine IT vendors are going to leverage this renewed market interest to facilitate visionary patient services, supported by the latest clinical and academic evidence.

Key Takeaway:

Top vendors will digitize and automate the process of patient data capture, analysis, and reporting. They will help generate patient-specific treatment options and recommend potential recovery plans based on each patient's clinical and genomic profiles. Physicians will be able to validate these auto-generated clinical pathways based on their experience and knowledge.

Table of Contents

1. EXECUTIVE SUMMARY

  • Global Precision Medicine IT Market Snapshot
  • Global Precision Medicine IT Solutions for Oncology-Analysis of Companies to Action
  • Global Precision Medicine IT Solutions for Oncology-Analysis of Companies to Action (continued)
  • Strategic Imperatives for Industry Stakeholders to Explore Precision Medicine
  • Precision Medicine-Regional Market Overview
  • Key Questions this Study will Answer
  • Precision Medicine-Future Impact on Healthcare
  • Precision Medicine-Strategic Imperatives for Success and Growth

2. COMPANIES TO ACTION OVERVIEW

  • Industry Convergence Driving Disruption and Innovation
  • Convergence in Healthcare Creates Both Opportunities and Threats
  • Frost & Sullivan Companies to Action Have the Potential to Disrupt Current Healthcare Industry Paradigms

3. DIGITAL HEALTH INDUSTRY SNAPSHOT

  • Digital Health Benefits from Broader Industry Convergence
  • Digital Health Priorities
  • Digital Health Market Segmentation and Convergence

4. PRECISION MEDICINE FOR ONCOLOGY MARKET OVERVIEW

  • What is Precision Medicine?
  • Market Challenges, Opportunities, and Concerns
  • Current State of Precision Medicine Adoption
  • Key Data Sources for Precision Medicine
  • Impact of Precision Medicine on Oncology
  • Impact of Key Market Influencers
  • Operational Architecture of Precision Medicine for Oncology
  • Operational Architecture of Precision Medicine for Oncology Explained
  • Stakeholders' Digital Health Solutions
  • Digital Health Solutions Applicable Across the Care Continuum
  • Digital Health Solutions Applicable Across the Care Continuum (continued)
  • Digital Health Solutions Applicable Across the Care Continuum (continued)
  • Digital Health Solutions Applicable Across the Care Continuum (continued)
  • Digital Health Companies Supporting Precision Medicine for Oncology-Vendor Landscape
  • Digital Health Companies Supporting Precision Medicine for Oncology-Vendor Landscape Discussion
  • Digital Health Companies Supporting Precision Medicine for Oncology-Vendor Landscape Discussion (continued)
  • Top Industry Needs and Vendor Strategies
  • Precision Medicine IT Solutions for Oncology-C2A Key Findings

5. C2A PROFILES

  • 2bPrecise (Allscripts)
  • 2bPrecise (Allscripts) (continued)
  • Cerner
  • Cerner (continued)
  • GenomOncology
  • GenomOncology (continued)
  • IBM Watson Health
  • IBM Watson Health (continued)
  • N-of-One
  • N-of-One (continued)
  • NantHealth
  • NantHealth (continued)
  • Navican (an Intermountain Healthcare Company)
  • Navican (an Intermountain Healthcare Company) (continued)
  • Quest Diagnostics
  • Quest Diagnostics (continued)
  • Royal Philips
  • Royal Philips (continued)
  • Via Oncology
  • Via Oncology (continued)

6. THE LAST WORD

  • Precision Medicine-Future Impact on Healthcare
  • Precision Medicine-Strategic Imperatives for Success and Growth
  • Legal Disclaimer

7. APPENDIX

  • List of Vendors Assessed
  • List of Vendors Assessed (continued)
  • List of Vendors Assessed (continued)
  • Abbreviation List

8. THE FROST & SULLIVAN STORY

  • The Frost & Sullivan Story
  • Value Proposition-Future of Your Company & Career
  • Global Perspective
  • Industry Convergence
  • 360° Research Perspective
  • Implementation Excellence
  • Our Blue Ocean Strategy
Back to Top